ANCA-Associated Vasculitides
Immunological and Clinical Aspects
Seiten
1993
Kluwer Academic/Plenum Publishers (Verlag)
978-0-306-44573-6 (ISBN)
Kluwer Academic/Plenum Publishers (Verlag)
978-0-306-44573-6 (ISBN)
Proceedings of the Fourth International Workshop on ANCA and the Second International Colloquium on Wegener's Granulomatosis and Vasculitic Disorders held in Lubeck, Germany, May 28-30, 1992
WEGENER'S GRANULOMATOSIS & ANCA-ASSOCIATED DISEASES: THE STORY CONTINUES The disease now designated as Wegener's granulomatosis (WG) was first described in 1931 by Heinz Klinger, who considered it to be a special form of polyarteritis nodosa. Klinger's friend, Friedrich Wegener, expanded on the first observations and interpreted the pathological and clinical fmdings to represent a distinct disease entity (Wegener, 1939). He described this entity as a "peculiar rhinogenous granulomatosis with a unique participation of the arterial system and the kidneys". Later, Godman and Churg (1954) established the classical diagnostic criteria (the "WG triad"): granuloma, vasculitis, and glomerulonephritis. In 1958 Walton pointed out the poor prognosis of WG based on a small number of published cases (mean survival time: 5 months). In 1966 Carrington and Liebow reported "limited forms" of WG with a defmitely more favorable prognosis. Since then positive results have been reported with cyclophosphamide therapy. In addition, a retrospective study of combined low-dose cyclophosphamide and prednisolone in 85 WG patients over a period of 21 years found a similarly encouraging outcome.
The*latter experience led to the current "standard" treatment protocol (FAUCI et al. , 1973 and 1983). More recently, strong evidence has emerged that some of the morbidity and mortality ofWG - and other types of systemic vasculitis - may be a consequence of this treatment (Hoffman et al. , 1992).
WEGENER'S GRANULOMATOSIS & ANCA-ASSOCIATED DISEASES: THE STORY CONTINUES The disease now designated as Wegener's granulomatosis (WG) was first described in 1931 by Heinz Klinger, who considered it to be a special form of polyarteritis nodosa. Klinger's friend, Friedrich Wegener, expanded on the first observations and interpreted the pathological and clinical fmdings to represent a distinct disease entity (Wegener, 1939). He described this entity as a "peculiar rhinogenous granulomatosis with a unique participation of the arterial system and the kidneys". Later, Godman and Churg (1954) established the classical diagnostic criteria (the "WG triad"): granuloma, vasculitis, and glomerulonephritis. In 1958 Walton pointed out the poor prognosis of WG based on a small number of published cases (mean survival time: 5 months). In 1966 Carrington and Liebow reported "limited forms" of WG with a defmitely more favorable prognosis. Since then positive results have been reported with cyclophosphamide therapy. In addition, a retrospective study of combined low-dose cyclophosphamide and prednisolone in 85 WG patients over a period of 21 years found a similarly encouraging outcome.
The*latter experience led to the current "standard" treatment protocol (FAUCI et al. , 1973 and 1983). More recently, strong evidence has emerged that some of the morbidity and mortality ofWG - and other types of systemic vasculitis - may be a consequence of this treatment (Hoffman et al. , 1992).
Friedrich Wegener and the Nature of Fame.- Pathophysiological Aspects and Antigen Specificity.- Clinical Aspects of Wegener’s Granulomatosis and other ANCA-Associated Diseases.
| Erscheint lt. Verlag | 30.11.1993 |
|---|---|
| Reihe/Serie | Advances in Experimental Medicine and Biology ; 336 |
| Zusatzinfo | XX, 552 p. |
| Verlagsort | New York |
| Sprache | englisch |
| Maße | 156 x 234 mm |
| Themenwelt | Medizinische Fachgebiete ► Innere Medizin ► Hämatologie |
| Naturwissenschaften ► Biologie ► Zoologie | |
| ISBN-10 | 0-306-44573-5 / 0306445735 |
| ISBN-13 | 978-0-306-44573-6 / 9780306445736 |
| Zustand | Neuware |
| Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Hämatologie und Internistische Onkologie
Buch | Softcover (2023)
ecomed-Storck GmbH (Verlag)
CHF 179,95
Buch | Softcover (2024)
Urban & Fischer in Elsevier (Verlag)
CHF 73,00
